


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kaisa Health Group Holdings Limited**  
**佳兆業健康集團控股有限公司**  
*(Incorporated in Bermuda with limited liability)*  
**(Stock Code: 876)**

**CANCELLATION OF GRANT OF SHARE OPTIONS**

Reference is made to the announcement of Kaisa Health Group Holdings Limited (the “**Company**”) dated 12 August 2021 (the “**Announcement**”) in relation to the grant of share options to three eligible participants (the “**Grant**”). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

Under Rule 17.05 of the Listing Rules, among others, the Company may not grant any option during the period commencing one month immediately before the earlier of (1) the date of the board meeting (as such date is first notified to the Stock Exchange under the Listing Rules) for approving the Company’s results for any year, half-year, quarterly or any other interim period (whether or not required under the Listing Rules); and (2) the deadline for the Company to announce its results for any year or half-year under the Listing Rules or quarterly or any other interim period (whether or not required under the Listing Rules), and ending on the date of the results announcement.

In order to comply with Rule 17.05 of the Listing Rules, the Company has cancelled the Grant on 12 August 2021. The Grant has not been accepted.

The Company will make an announcement in relation to the Grant at another time in compliance with the Listing Rules.

On behalf of the Board  
**Kaisa Health Group Holdings Limited**  
**Zhang Huagang**  
*Chairman*

Hong Kong, 16 August 2021

*As at the date of this announcement, the Board comprises five executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman), and Mr. Kwok Ying Shing, and Ms. Kwok Ho Lai and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping, and Ms. Li Yonglan.*